½ÃÀ庸°í¼­
»óǰÄÚµå
1815944

µ­±â¿­ : ¼¼°è ÀÓ»ó½ÃÇè ¸®ºä(2025³â)

Dengue Fever - Global Clinical Trials Review, 2025

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: GlobalData | ÆäÀÌÁö Á¤º¸: ¿µ¹® 192 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

GlobalDataÀÇ ÀÓ»ó½ÃÇè º¸°í¼­ 'µ­±â¿­ : ¼¼°è ÀÓ»ó½ÃÇè ¸®ºä(2025³â)'´Â µ­±â¿­ ÀÓ»ó½ÃÇè ½Ã³ª¸®¿À¿¡ ´ëÇÑ °³¿ä¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ º¸°í¼­´Â µ­±â¿­ °ü·Ã ÀÓ»ó½ÃÇè°ú °ü·ÃµÈ ÁÖ¿ä µ¥ÀÌÅ͸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ º¸°í¼­¿¡´Â Àü ¼¼°è ÁÖ¿ä ±¹°¡¿¡¼­ ½Ç½ÃµÈ ½ÃÇèÀÇ ¼ö¿Í Æò±Õ µî·ÏÀÚ ¼ö¿¡ ´ëÇÑ °³¿ä°¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ÀÌ º¸°í¼­´Â Áö¿ª, ±¹°¡(G7 &E7), ±¹°¡º°, ´Ü°èº°, ÀÓ»ó½ÃÇè ÇöȲ, Æò°¡ÁöÇ¥ ÇöȲ, ½ºÆù¼­ À¯Çüº° Áúȯ ÀÓ»ó½ÃÇèÀ» ´Ù·ç°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇöÀç ÁøÇà ÁßÀÎ ÀÓ»ó½ÃÇè(ÁøÇà ÁßÀÎ ÀÓ»ó½ÃÇè ¼ö ±âÁØ)ÀÌ ÁøÇà ÁßÀÎ Àú¸íÇÑ ¾àǰµµ °ÔÀçµÇ¾î ÀÖ½À´Ï´Ù. GlobalDataÀÇ ÀÓ»ó½ÃÇè º¸°í¼­´Â GlobalDataÀÇ ÀÚü µ¥ÀÌÅͺ£À̽ºÀÎ Pharma-ÀÓ»ó½ÃÇè µ¥ÀÌÅͺ£À̽º¸¦ »ç¿ëÇÏ¿© ÀÛ¼ºµË´Ï´Ù. ÀÓ»ó½ÃÇèÀº Àü ¼¼°è 80°³ ÀÌ»óÀÇ ´Ù¾çÇÑ ÀÓ»ó½ÃÇè µî·Ï, ÄÁÆÛ·±½º, Àú³Î, ´º½º µîÀ» ÅëÇØ ¼öÁýµË´Ï´Ù. ÀÓ»ó½ÃÇè µ¥ÀÌÅͺ£À̽º´Â µ¿Àû ÇÁ·Î¼¼½º¿¡ ÀÇÇØ Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µË´Ï´Ù.

º» º¸°í¼­´Â ÀÇ»ç°áÁ¤ ´É·ÂÀ» Çâ»ó½Ã۰í, °æÀï ¿ìÀ§¸¦ È®º¸Çϱâ À§ÇÑ È¿°úÀûÀÎ ´ëÀÀ Àü·«À» ¼ö¸³ÇÏ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀÔ´Ï´Ù.

Âü°í: º» º¸°í¼­ÀÇ ÀϺΠ¼½¼ÇÀº ´ë»ó Áúȯ¿¡ ´ëÇÑ µ¥ÀÌÅÍÀÇ °¡¿ë¼º ¹× °ü·Ã¼º¿¡ µû¶ó »èÁ¦ ¶Ç´Â º¯°æµÉ ¼ö ÀÖ½À´Ï´Ù.

¹üÀ§

  • º» º¸°í¼­´Â Àü ¼¼°è ÀÓ»ó½ÃÇè ÇöȲ¿¡ ´ëÇÑ ½º³À¼¦À» Á¦°øÇÕ´Ï´Ù.
  • Áö¿ª, ±¹°¡(G7 &E7), ÀÓ»ó½ÃÇè ÇöȲ, ½ÃÇè ´Ü°è, ½ºÆù¼­ À¯Çü, Æò°¡ÁöÇ¥ »óź°·Î ÀÓ»ó½ÃÇè °ü·Ã ÃÖ»óÀ§ µ¥ÀÌÅ͸¦ Á¦°øÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­¿¡¼­´Â °ü·Ã »óÀ§ ±â¾÷À» °ËÅäÇϰí, ÇØ´ç ±â¾÷°ú °ü·ÃµÈ ¸ðµç ÀÓ»ó½ÃÇè(ÀÓ»ó½ÃÇè Á¦¸ñ, ´Ü°è, »óÅÂ)À» ³ª¿­Çϰí ÀÖ½À´Ï´Ù.
  • º¸°í¼­¿¡¼­´Â ¹Ì´Þ¼ºµÈ ½ÃÇè(Á¾·á, Áß´Ü, öȸ)À» ¹Ì´Þ¼º ÀÌÀ¯¿Í ÇÔ²² Á¦°øÇÕ´Ï´Ù.
  • º¸°í¼­´Â Áö³­ 5³â°£ÀÇ µî·Ï µ¿ÇâÀ» Á¦°øÇÕ´Ï´Ù.
  • Áö³­ 3°³¿ù°£ÀÇ ÃֽŠ´º½º

Âü°í: º¸°í¼­ÀÇ ÀϺΠ¼½¼ÇÀº ´ë»ó Áúȯ¿¡ ´ëÇÑ µ¥ÀÌÅÍÀÇ °¡¿ë¼º ¹× °ü·Ã¼º¿¡ µû¶ó »èÁ¦ ¶Ç´Â º¯°æµÉ ¼ö ÀÖ½À´Ï´Ù.

±¸¸Å ÀÌÀ¯

  • ÅõÀÚ °ü·Ã ÁÖ¿ä »ç¾÷ Àü·« ¼ö¸³¿¡ µµ¿ò
  • ½Ã°£°ú ºñ¿ëÀ» Àý¾àÇÒ ¼ö ÀÖ´Â ÀÓ»ó½ÃÇè ½Ç½Ã¿¡ ÀûÇÕÇÑ Àå¼Ò¸¦ ½Äº°ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.
  • ÁÖ¿ä ºñÁî´Ï½º ±âȸ¸¦ ½Äº°ÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â ¼¼°è ÀÓ»ó½ÃÇè ½ÃÀå ÃÖ°í ¼öÁØÀÇ ºÐ¼® Á¦°ø
  • ¼¼°è Ä¡·áÁ¦ ½ÃÀåÀÇ ±¹°¡º° ÀÓ»ó½ÃÇè ¼ö ¹× µî·Ï µ¿Çâ¿¡ ´ëÇÑ ÀÌÇØ Áö¿ø
  • ¿Ï·áµÈ ÀÓ»ó½ÃÇè°ú ¹Ì¿Ï·á(Á¾·á, Áß´Ü, öȸ) ÀÓ»ó½ÃÇèÀÇ ºñ±³ ½Ã³ª¸®¿À¸¦ Á¦°øÇÔÀ¸·Î½á ÀÓ»ó½ÃÇè ¼º°ø·üÀ» ÇØ¼®ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.
  • ¼¼°è, Áö¿ª, ±¹°¡ ´ÜÀ§ÀÇ ÀûÀÀÁõ¿¡ ´ëÇÑ ÀÓ»ó½ÃÇè Æò°¡¸¦ ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù.

Âü°í: º» º¸°í¼­ÀÇ ÀϺΠ¼½¼ÇÀº ´ë»ó Áúȯ¿¡ ´ëÇÑ µ¥ÀÌÅÍÀÇ °¡¿ë¼º ¹× °ü·Ã¼º¿¡ µû¶ó »èÁ¦ ¶Ç´Â º¯°æµÉ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Ç¥ ¸®½ºÆ®

µµÇ¥

  • º¸°í¼­ °¡ÀÌ´ø½º
  • GlobalDataÀÇ ÀÓ»ó½ÃÇè Á¶»ç ¹üÀ§
  • Áö¿ªº° ÀÓ»ó½ÃÇè
  • ±¹°¡º° ÀÓ»ó½ÃÇè°ú Æò±Õ µî·ÏÀÚ¼ö
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ±â¿©µµ ÁÖ¿ä 5°³±¹
  • À¯·´ ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ±â¿©µµ ÁÖ¿ä 5°³±¹
  • ºÏ¹Ì ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ±â¿© ÁÖ¿ä ±¹°¡
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ±â¿© ÁÖ¿ä ±¹°¡
  • Áß³²¹Ì ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ±â¿©µµ ÁÖ¿ä 5°³±¹
  • G7 ±¹°¡ÀÇ ÀÓ»ó½ÃÇè : µ­±â¿­ ÀÓ»ó½ÃÇè°ú °¨¿°Áõ ÀÓ»ó½ÃÇè ºñÀ²
  • G7 ±¹°¡ÀÇ »óº° ÀÓ»ó½ÃÇè
  • G7 ±¹°¡ÀÇ ÀÓ»ó½ÃÇè »óȲ
  • E7 ±¹°¡º° ÀÓ»ó½ÃÇè : µ­±â¿­°ú °¨¿°Áõ ÀÓ»ó½ÃÇè ºñÀ²
  • E7 ±¹°¡ÀÇ »óº° ÀÓ»ó½ÃÇè
  • E7 ±¹°¡ÀÇ ÀÓ»ó½ÃÇè(½ÃÇè »óȲº°)
  • »óº° ÀÓ»ó½ÃÇè
  • ÁøÇà ÁßÀÎ ½ÃÇè(»óº°)
  • ½ÃÇè »óȲº° ÀÓ»ó½ÃÇè
  • ¿£µåÆ÷ÀÎÆ® ÇöȲº° ÀÓ»ó½ÃÇè
  • ÀÏÁ¤±â°£¿¡ °ÉÃļ­ ¸ðÁýµÈ ÇÇÇèÀÚ
  • ½ºÆù¼­ À¯Çüº° ÀÓ»ó½ÃÇè
  • Àú¸íÇÑ ½ºÆù¼­
  • µ­±â¿­ Ä¡·áÁ¦ ÀÓ»ó½ÃÇè¿¡ Âü°¡Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷
  • Àú¸íÇÑ ¾à¹°
  • µ­±â¿­¿¡ °üÇÑ ÃֽŠÀÓ»ó½ÃÇè ´º½º
  • 2025³â 8¿ù 21ÀÏ: µ­±â ¹ÙÀÌ·¯½º °¨¿° ¹é½Å KD-382ÀÇ 2»ó ÀÓ»ó½ÃÇè ½ÃÀÛ ¹ßÇ¥
  • 2025³â 8¿ù 1ÀÏ: µ­±â ¹é½Å 3»ó ÀÓ»ó½ÃÇè Âü°¡ÀÚ ¸ðÁý·ü 70% ´Þ¼º
  • 2025³â 7¿ù 13ÀÏ: Àεµ ÃÖÃÊ µ­±â¿­ ¹é½Å 3»ó ÀÓ»ó½ÃÇè Âü°¡ÀÚ ¸ðÁý, 10¿ù±îÁö ¿Ï·á ¿¹Á¤: ICMR
  • 2025³â 6¿ù 12ÀÏ: ¸ÓÅ©, µ­±â¿­ ¹é½Å Èĺ¸¹°Áú 3»ó ¿¬±¸ °³½Ã
  • 2025³â 6¿ù 4ÀÏ: SynAct Pharma, ¼±µµ¹°Áú Resomelagon(AP1189) °³¹ß Àü·« °³¼±
  • ÀÓ»ó½ÃÇè °³¿ä ÇöȲ

ºÎ·Ï

LSH 25.09.25

GlobalData's clinical trial report, "Dengue Fever - Global Clinical Trials Review, 2025" provides an overview of Dengue Fever Clinical trials scenario. This report provides top line data relating to the clinical trials on Dengue Fever. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Dengue Fever to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Dengue Fever to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Dengue Fever Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Dengue Fever
  • Aug 21, 2025: Announcement of the Start of a Phase II Clinical Trial of KD-382, a Vaccine for Dengue Virus Infection
  • Aug 01, 2025: 70% Enrolment of Participants for Phase III Clinical Trial of Dengue Vaccine Completed
  • Jul 13, 2025: Phase-3 Clinical Trial Enrolment for India's First Dengue Vaccine to Be Completed by October: ICMR
  • Jun 12, 2025: Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
  • Jun 04, 2025: SynAct Pharma Refines Development Strategy for Lead Compound Resomelagon (AP1189)
  • Clinical Trial Profile Snapshots

Appendix

  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About GlobalData
  • Contact Us
  • Source
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦